TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32075958

Group type: EXPERIMENTAL
Intervention: Oral cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smoked cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34181037

Group type: EXPERIMENTAL
Intervention: Heart-liver transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ductal stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled reoxygenation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid palliation strategy
Number of subjects: 0
Study: 35147645

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Photo-biomodulation (PBM)
Number of subjects: 30
Study: 32954832

Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring and remote counselling (BPTM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240
Study: 32542854

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 100
Study: 34816373

Group type: EXPERIMENTAL
Intervention: HLX03
Number of subjects: 262

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 262
Study: 34143779

Group type: EXPERIMENTAL
Intervention: Enhanced adherence support with adherence feedback from intracellular tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard adherence support (counseling, 2-way SMS, and adherence clubs)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Both groups (Enhanced and Standard adherence support)
Number of subjects: 451
Study: 34224478

Group type: EXPERIMENTAL
Intervention: Intraocular lens with a 7.0 mm optic and plate haptic design (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraocular lens with a 6.0 mm optic and C-loop haptic design (Group 2)
Number of subjects: 120
Study: 32811186

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 92
Study: 34490460

Group type: EXPERIMENTAL
Intervention: WeChat follow‐up group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Outpatient follow‐up group
Number of subjects: 168
Study: 32216555

Group type: EXPERIMENTAL
Intervention: Colistin (20 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tylosin (55 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlortetracycline (CTC, 55 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35641878

Group type: EXPERIMENTAL
Intervention: IV lignocaine infusion (1.5 mg/kg at induction followed by 1.5 mg/kg/h for 1 hour in PACU)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IV lignocaine infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline IV infusion
Number of subjects: 70
Study: 34058036

Group type: EXPERIMENTAL
Intervention: Nebulised amphotericin B
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral itraconazole
Number of subjects: 33
Study: 35465764

Group type: EXPERIMENTAL
Intervention: Simple opt-in message
Number of subjects: 610

Group type: COMPARATOR
Intervention: Recommendation by the hospital
Number of subjects: 610

Group type: COMPARATOR
Intervention: Community-oriented message
Number of subjects: 610

Group type: COMPARATOR
Intervention: Acknowledgment of vaccine hesitancy
Number of subjects: 610

Group type: COMPARATOR
Intervention: Overall willingness to accept vaccination in the ED
Number of subjects: 610
Study: 32522422

Group type: EXPERIMENTAL
Intervention: Fit & Strong! Program (8-week multicomponent program)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 32054426

Group type: EXPERIMENTAL
Intervention: Dental scaling and root planing (SRP) for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 10
Study: 35432165

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 36
Study: 32539426

Group type: EXPERIMENTAL
Intervention: Acupuncture-assisted anesthesia (AAA) with electrostimulation (2-4 Hz) at LI4 and PC6, and additional stimulation at the lump site (30 Hz)
Number of subjects: 17
Study: 33125753

Group type: EXPERIMENTAL
Intervention: SAR247799 1 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SAR247799 5 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (positive control)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 32173316

Group type: EXPERIMENTAL
Intervention: Distance from urban edge (0 m, 50 m, 100 m, 500 m)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Normalized Difference Vegetation Index (NDVI) (low, medium, high)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Morisita overlap index
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Aedes albopictus and Ae. aegypti
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Forest specialists (Haemagogus janthinomys, Sabethes glaucodaemon, Sa. tridentatus)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Trichoprosopon digitatum and Psorophora amazonica
Number of subjects: 1172
Study: 34299814

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 307
Study: 33257343

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (10 mg orally)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg orally, max 975 mg)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 236

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 236
Study: 36229087

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering
Number of subjects: 8820

Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) lowering
Number of subjects: 8820
Study: 32994374

Group type: EXPERIMENTAL
Intervention: Stigma Assessment Tool for Family Caregivers of People with Mental Illness (SAT-FAM)
Number of subjects: 286
Study: 35274750

Group type: EXPERIMENTAL
Intervention: Function Focused Care for Acute Care (FFC-AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FFC-AC-EIT (Function Focused Care integrated with Evidence Integration Triangle)
Number of subjects: 0
Study: 33794131

Group type: EXPERIMENTAL
Intervention: Protocolized postextubation respiratory support (noninvasive ventilation for suspected hypercapnia, high-flow nasal cannula for others)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Usual care (postextubation management at the discretion of treating clinicians)
Number of subjects: 751
Study: 35878575

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Interferon beta-1a (IFNb-1a)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 55
Study: 36309690

Group type: EXPERIMENTAL
Intervention: Targeted gluteal intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 27
Study: 34020931

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus docetaxel (75 mg/m2 q3w for ten cycles)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus docetaxel
Number of subjects: 413
Study: 32268604

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 34391740

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Change in KCCQ-OS from baseline to 1 month
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Change in 6MWD from baseline to 1 month
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Baseline 6MWD
Number of subjects: 604
Study: 36109453

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 70
Study: 33146791

Group type: EXPERIMENTAL
Intervention: Integrated model using clinical, CT, PET/CT, and histopathological features
Number of subjects: 399

Group type: COMPARATOR
Intervention: Histopathological features
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Nomogram with clinical, imaging, and histopathological features
Number of subjects: 399
Study: 33803243

Group type: EXPERIMENTAL
Intervention: Pressured sexting
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Receiving unsolicited sexts
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Forwarding sexts without permission
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Asking someone for sexts
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Being asked to send a sext
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Consensual sexting
Number of subjects: 2199
Study: 35708743

Group type: EXPERIMENTAL
Intervention: Web- and smartphone-based PA program
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (usual PA advice)
Number of subjects: 228
Study: 33962517

Group type: EXPERIMENTAL
Intervention: Active Plus intervention
Number of subjects: 585
Study: 32392455

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lurasidone
Number of subjects: 0
Study: 35819570

Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Number of subjects: 742
Study: 34581194

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 4077

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 4077
Study: 95358022

Group type: EXPERIMENTAL
Intervention: S + preS2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Any vaccine used
Number of subjects: 0
Study: 34889883

Group type: EXPERIMENTAL
Intervention: Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34969632

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab
Number of subjects: 153

Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab
Number of subjects: 153
Study: 33883195

Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin (BBI) regimen
Number of subjects: 305

Group type: COMPARATOR
Intervention: Fixed ratio of basal insulin plus GLP-1RA (fixed-combo group)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Basal insulin plus SGLT2 inhibitor (gliflo-combo group)
Number of subjects: 305
Study: 33734144

Group type: EXPERIMENTAL
Intervention: Continuous Thoracic Paravertebral Block (TPVB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous Pectoral Nerve Block (PEC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous Opioid Analgesia (PCA-M)
Number of subjects: 90
Study: 33137422

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (10 sessions over two weeks, continuous ultrasound at an intensity of 0.7 to 0.8 w/cm2, frequency of 3 MHz for 5 minutes) plus standard care (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care alone (n = 15)
Number of subjects: 31
Study: 32037263

Group type: EXPERIMENTAL
Intervention: 12-week hospital based physical therapy (intervention group, n=8)
Number of subjects: 15
Study: 33544066

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 62
Study: 32636128

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 32694482

Group type: EXPERIMENTAL
Intervention: REBUS-guided TBC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-REBUS TBC
Number of subjects: 10
Study: 32453406

Group type: EXPERIMENTAL
Intervention: Withdrawal plus preventive treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preventive treatment without withdrawal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Withdrawal with optional preventive treatment 2 months after withdrawal
Number of subjects: 120
Study: 34186112

Group type: EXPERIMENTAL
Intervention: Milrinone after cardiac surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single Ventricle Reconstruction trial
Number of subjects: 0
Study: 32294074

Group type: EXPERIMENTAL
Intervention: Women who previously underwent cosmetic procedures
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (women without a history of cosmetic procedures)
Number of subjects: 40
Study: 35483576

Group type: EXPERIMENTAL
Intervention: Decision support tools (DSTs) including online patient decision aids, consultation cards, and decision cards; training on how to apply shared decision making (SDM) during clinician-patient encounters
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Decision support tools (DSTs)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: SDM training for surgeons
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Decision aid for patients
Number of subjects: 342
Study: 36942420

Group type: EXPERIMENTAL
Intervention: Combination of exercise and liraglutide 3.0 mg/d
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/d
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 32342247

Group type: EXPERIMENTAL
Intervention: Perioperative GL group receiving 100 mL of 5% glucose solution immediately after local anesthesia
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Postoperative GL group receiving 100 mL of 5% glucose solution immediately after surgery completion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group receiving glucose-free sodium lactate Ringer's solution
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressure and heart rate
Number of subjects: 54
Study: 35453088

Group type: EXPERIMENTAL
Intervention: MPS Ion AmpliSeq™ HID Y‐SNP Research Panel v1
Number of subjects: 182
Study: 34080920

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg at bedtime)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33036063

Group type: EXPERIMENTAL
Intervention: Patient-reported longer estimate
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Caregiver-reported longer estimate
Number of subjects: 354

Group type: COMPARATOR
Intervention: Patients screening positive for polypharmacy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Caregivers reporting greater distress
Number of subjects: 354

Group type: COMPARATOR
Intervention: Caregivers when patients screened positive for polypharmacy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Caregivers when patients had lower perceived self-efficacy in interacting with physicians
Number of subjects: 354
Study: 34187758

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) protocol for 12 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study: 35775129

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) protocol with 4.45 Gy dose increase
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control protocol (10 × 4 Gy)
Number of subjects: 57
Study: 33779991

Group type: EXPERIMENTAL
Intervention: High-intensity training (n = 24)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-intensity training (n = 23)
Number of subjects: 34
Study: 33334330

Group type: EXPERIMENTAL
Intervention: Fertility educational program (verbal and virtual educational package at five time episodes within 4 weeks)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Typical premarital counselling training
Number of subjects: 1240
Study: 36353530

Group type: EXPERIMENTAL
Intervention: TOLF intervention group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 33541062

Group type: EXPERIMENTAL
Intervention: Pendulum treatment for molar distalization over 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pendulum treatment for molar distalization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment) after one year
Number of subjects: 12
Study: 32865062

Group type: EXPERIMENTAL
Intervention: Iodine-125 seed interstitial brachytherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chemotherapy perfusion
Number of subjects: 165
Study: 33626028

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (POH) defined as a single measurement of mean arterial pressure (MAP) below thresholds of ≤75 mm Hg, ≤65 mm Hg, and ≤55 mm Hg.
Number of subjects: 67968

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (POH) defined as a single measurement of MAP below thresholds of ≤75 mm Hg, ≤65 mm Hg, and ≤55 mm Hg.
Number of subjects: 67968

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (POH) with intraoperative hypotension (IOH) defined as intraoperative MAP ≤65 mm Hg.
Number of subjects: 67968

Group type: COMPARATOR
Intervention: Postoperative hypotension (POH) without intraoperative hypotension (IOH).
Number of subjects: 67968
Study: 35754130

Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed whey-protein formula (eHWF)
Number of subjects: 34
Study: 32863246

Group type: EXPERIMENTAL
Intervention: OCT-guided coronary stent implantation
Number of subjects: 2490

Group type: COMPARATOR
Intervention: Angiography-guided coronary stent implantation
Number of subjects: 2490
Study: 36154947

Group type: EXPERIMENTAL
Intervention: Enhancing Contact Model (ECM)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Psychoeducational Family Intervention (PFI)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 253
Study: 34433843

Group type: EXPERIMENTAL
Intervention: Micro-hybrid composite restorations (Group Am, n=44)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Nano-ceramic composite restorations (Group An, n=42)
Number of subjects: 124
Study: 32396592

Group type: EXPERIMENTAL
Intervention: Cranberry juice drink (375 mg total flavan‐3‐ols)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice drink (716 mg total flavan‐3‐ols)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice drink (1131 mg total flavan‐3‐ols)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice drink (1396 mg total flavan‐3‐ols)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cranberry juice drink (1741 mg total flavan‐3‐ols)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 10
Study: 33805346

Group type: EXPERIMENTAL
Intervention: Serum urea level
Number of subjects: 13430
Study: 32378071

Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6 (oxaliplatin in combination with 5‐fluorouracil and l‐leucovorin)
Number of subjects: 35
Study: 32102813

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 54
Study: 36412341

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri UBLRU‐87
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum UBBB‐55
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blend of Lactobacillus reuteri and Bifidobacterium bifidum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (curd with no probiotic)
Number of subjects: 60
Study: 33415858

Group type: EXPERIMENTAL
Intervention: Acupuncture group (round magnetic needle tapping plus acupuncture at Qi Shen Zhen)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medication group (Escitalopram Oxalate tablets 5-20 mg/d)
Number of subjects: 57
Study: 34696941

Group type: EXPERIMENTAL
Intervention: Descriptive format (fact box)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Simulated experience format (interactive simulation)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 300
Study: 33403921

Group type: EXPERIMENTAL
Intervention: Breath-focused, digital meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 33250205

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 34219669

Group type: EXPERIMENTAL
Intervention: QFR-consistent PCI
Number of subjects: 1391

Group type: COMPARATOR
Intervention: QFR-inconsistent PCI
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: QFR-consistent PCI (adjusted)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: QFR-inconsistent PCI (adjusted)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: QFR-consistent PCI (ischaemia-driven revascularisation)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: QFR-inconsistent PCI (ischaemia-driven revascularisation)
Number of subjects: 1391
Study: 34836079

Group type: EXPERIMENTAL
Intervention: EX (exercise routine only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EXDC (exercise + dietary counseling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EXCO (exercise + 2 g/day oil from Calanus finmarchicus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON (control group, no treatment)
Number of subjects: 0
Study: 32203595

Group type: EXPERIMENTAL
Intervention: Prism adaptation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Augmented surgery
Number of subjects: 40
Study: 34102553

Group type: EXPERIMENTAL
Intervention: Phone-based intervention under nurse guidance including home BP monitoring, medication reminders, and education on hypertension delivered weekly for 12 months.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Phone-based intervention under nurse guidance.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care as determined by local guidelines.
Number of subjects: 500
Study: 33109273

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 88